Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Rhenovia Files Two Patent Applications for RHEpatch™

Published: Friday, March 22, 2013
Last Updated: Friday, March 22, 2013
Bookmark and Share
An electronic transdermal patch for controlled drug delivery.

Rhenovia Pharma has announced that it has filed two patent applications for RHEpatch™, Rhenovia’s electronic transdermal patch for people suffering from chronic diseases.

RHEpatch was originally designed to optimize the delivery of drugs to patients suffering from diseases of the nervous system. However, Rhenovia now expects it to have a considerable impact across the entire health sector.

Its principal aim is to control dosing, treatment time and duration, day and night, for up to seven drugs administered to each patient. Control is achieved through a built-in electronic system pre-programmed by the doctor.

RHEpatch thus provides better control over the delivery of several drugs prescribed as a polytherapy, especially for the elderly.

RHEpatch is also designed to deliver the combinations of compounds needed to treat complex nervous system diseases such as Alzheimer’s disease.

It will also automatically control the administration of drugs, thus reducing the risk of patients forgetting. This facilitates treatment of patients with reduced mobility and prevents confused patients from taking repeated doses of drugs.

RHEpatch has many advantages over existing transdermal patches, which have drug release systems that are mainly passive (the treatment begins when the patch is put on and ends when it is taken off).

RHEpatch also indicates the amount of product actually delivered and the amount remaining in the patch.

In addition, unlike other transdermal patches, Rhenovia’s technology allows closely-controlled administration of several drugs through the same vector.

“This unique drug delivery device is going to have a major impact on the way medicines are used in the coming years,” said Dr. Serge Bischoff, president and CEO of Rhenovia. “It will enable doctors and nurses to manage treatment regimes more efficiently and more safely, as well as significantly improving patients’ quality of life.”

“RHEpatch is going to improve the treatment of diseases as complex as Parkinson’s, Alzheimer’s and Huntington’s, which require polytherapies for optimal efficacy,” said Professor Michel Baudry, vice-president and scientific director of Rhenovia.

“Delivering several drugs to the right place at the right time and in the right dose is a major challenge,” said Michel Faupel, vice-president of Rhenovia and the designer of RHEpatch.

Faupel continued, “Up to now, no one has succeeded in doing that satisfactorily. Yet this kind of approach is essential for ensuring effective long-term treatment of chronic diseases. By combining multitherapies derived from Rhenovia’s simulators with the controlled administration afforded by this intelligent patch, Rhenovia is convinced it can meet that challenge.”

Rhenovia’s industrial partner, Portmann Instruments AG, also contributed to the design of RHEpatch.

Portmann Instruments, which is based in Biel-Benken, Switzerland, is specialized in high-precision instrumentation and manufactures customized components for RHEpatch.

With the completion of a three-year EU Eurostars partnership program between Rhenovia and Portmann Instruments, RHEpatch has now reached the pre-industrialization prototype stage.

Following technological and biological proof-of-concept studies, Rhenovia is now looking for pharmaceutical, industrial and financial partners to move on to the industrialization and out-licensing stage.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
Have Your Drug Nano-Delivered Via Microbubble
A UC engineering professor is working to develop effective nanoparticle-bubble drug delivery systems to access precise locations in the body to treat medical conditions such as cancer, eye disease and spinal disc degeneration.
Potential New Diagnosis and Therapy for Breast Cancer
Scientists at the University of York, using clinical specimens from charity Breast Cancer Now’s Tissue Bank, have conducted new research into a specific sodium channel that indicates the presence of cancer cells and affects tumour growth rates.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos